• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Enhancement of cell surface expression and receptor functions of membrane progestin receptor alpha (mPRα) by progesterone receptor membrane component 1 (PGRMC1): evidence for a role of PGRMC1 as an adaptor protein for steroid receptors.
Abstract A variety of functions have been proposed for progesterone receptor membrane component 1 (PGRMC1), including acting as a component of a membrane progestin receptor and as an adaptor protein. Here we show that stable over expression of human PGRMC1 in progesterone receptor-negative breast cancer cell lines causes increased expression of PGRMC1 and membrane progesterone receptor alpha (mPRα) on cell membranes which is associated with increased specific [(3)H]progesterone binding. The membrane progestin binding affinity and specificity were characteristic of mPRα, with a Kd of 4.7 nM and high affinity for ...
Source: Endocrinology - January 1, 2014 Category: Endocrinology Authors: Thomas P, Pang Y, Dong J Tags: Endocrinology Source Type: research

New cholesterol drug shows promise
Conclusion Media headlines reporting on this phase I trial concentrated on the secondary outcome (that ALN-PCS reduced LDL cholesterol levels). However, these results will need to be confirmed during phase II and phase III clinical trials, which will involve more participants who would normally receive cholesterol-lowering treatment. While it is tempting to focus on the results of the cholesterol levels, phase I clinical trials are designed to test the safety of a new drug to make sure it is safe enough to test further. They also aim to determine what the highest tolerable dose is, so the appropriate one can be used in la...
Source: NHS News Feed - October 3, 2013 Category: Consumer Health News Tags: Heart/lungs Medical practice Medication Source Type: news

Pages: 1  2  3  4  5